News · 26 weeks31-50%
2025-12-142026-06-07
Mix1390d
- Other6(46%)
- SEC Filings6(46%)
- Leadership1(8%)
Latest news
25 items- SECBeyond Air Inc. filed SEC Form 8-K: Other Events8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air Receives Nasdaq Hearing Panel Decision Granting Continued ListingGARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's ("Nasdaq" or the "Exchange") Listing Rule 5550(a)(2) (the "Bid Price Rule") by July 31, 2026. The Company is fully compliant with all other continued listing requirements. "We appreciate the Panel's thoughtful review and support of our compliance plan,"
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)
- SECSEC Form DEF 14A filed by Beyond Air Inc.DEF 14A - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form PRE 14A filed by Beyond Air Inc.PRE 14A - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Other Events8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air to Participate in the D. Boral Capital Global Conference 2026GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York. Conference Format: One-on-one meetingsConference Dates: May 7thParticipants: Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air If you are interested in requesting a one-on-one meeting at the confere
- SECBeyond Air Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - Beyond Air, Inc. (0001641631) (Filer)
- PRBeyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)GARDEN CITY, N.Y., April 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced it has been awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization (GPO). Effective April 1, 2026, the agreement allows participating member hospitals and health systems to access the LungFit® PH system. This new agreement builds on Beyond Air's existing relationships with leading U.S. GPOs, including Vizient and Premier, Inc., further expanding access to a broad network of
- PRBeyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEOGARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company's current Chief Commercial Officer and Director, as Chief Executive Officer, effective today. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of th
- PRLife Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
- PRLife Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
- PRBeyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals Ltd. ("XTL") relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its ter
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)
- SECBeyond Air Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form 10-Q filed by Beyond Air Inc.10-Q - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form 424B3 filed by Beyond Air Inc.424B3 - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form EFFECT filed by Beyond Air Inc.EFFECT - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECSEC Form S-3 filed by Beyond Air Inc.S-3 - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
- SECBeyond Air Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Beyond Air, Inc. (0001641631) (Filer)
XAIR FAQ
6 questionsWhat does Beyond Air Inc. do?
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond...Where does XAIR stock trade?
Beyond Air Inc. (XAIR) is listed on NASDAQ.What sector and industry is XAIR in?
Beyond Air Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about XAIR?
Beyond Air Inc. has had 5 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $1100.00 price target on 2025-07-17. Recent price targets range from $1000.00 to $1600.00.What companies are similar to XAIR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare XAIR side-by-side with any of them on Quantisnow.How can I track XAIR on Quantisnow?
Quantisnow aggregates Beyond Air Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XAIR to receive live email and push alerts on every new disclosure.